儿科

Demystifying Drug Dosing in Renal Dysfunction Pub Date : 2019-05-31 DOI:10.37573/9781585285525.008

J. Teruya

{"title":"儿科","authors":"J. Teruya","doi":"10.37573/9781585285525.008","DOIUrl":null,"url":null,"abstract":"Conclusions: BRAF mutation was more seen in a metastatic site rather than primary in melanoma (p=0.023). In colorectal adenocarcinoma, NRAS mutation was more likely persent in metastatic site than primary (p=0.048). We did not fi nd association with examined site in other analyzed mutations (KRAS, KIT, PIK3CA). These results suggest importance of consideration of disease site when analyzing mutational status. Probability of co-mutations in different pathways has signifi cance for decisions regarding therapy.","PeriodicalId":171073,"journal":{"name":"Demystifying Drug Dosing in Renal Dysfunction","volume":"49 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pediatrics\",\"authors\":\"J. Teruya\",\"doi\":\"10.37573/9781585285525.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Conclusions: BRAF mutation was more seen in a metastatic site rather than primary in melanoma (p=0.023). In colorectal adenocarcinoma, NRAS mutation was more likely persent in metastatic site than primary (p=0.048). We did not fi nd association with examined site in other analyzed mutations (KRAS, KIT, PIK3CA). These results suggest importance of consideration of disease site when analyzing mutational status. Probability of co-mutations in different pathways has signifi cance for decisions regarding therapy.\",\"PeriodicalId\":171073,\"journal\":{\"name\":\"Demystifying Drug Dosing in Renal Dysfunction\",\"volume\":\"49 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Demystifying Drug Dosing in Renal Dysfunction\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37573/9781585285525.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Demystifying Drug Dosing in Renal Dysfunction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37573/9781585285525.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

结论:BRAF突变更常见于转移部位，而非原发性黑色素瘤(p=0.023)。在结直肠癌中，NRAS突变在转移部位比原发部位更容易发生(p=0.048)。我们在其他分析的突变(KRAS, KIT, PIK3CA)中未发现与检测位点的关联。这些结果提示在分析突变状态时考虑疾病部位的重要性。不同途径的共突变概率对治疗决策具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pediatrics

Conclusions: BRAF mutation was more seen in a metastatic site rather than primary in melanoma (p=0.023). In colorectal adenocarcinoma, NRAS mutation was more likely persent in metastatic site than primary (p=0.048). We did not fi nd association with examined site in other analyzed mutations (KRAS, KIT, PIK3CA). These results suggest importance of consideration of disease site when analyzing mutational status. Probability of co-mutations in different pathways has signifi cance for decisions regarding therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Demystifying Drug Dosing in Renal Dysfunction

自引率

0.00%

发文量